COMMUNIQUÉS West-GlobeNewswire

IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH
03/11/2025
Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader [...]
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
03/11/2025
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology [...]
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
03/11/2025
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
03/11/2025
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Gazyva/Gazyvaro has the potential to be a transformative [...]
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
03/11/2025
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that [...]
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
03/11/2025
LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful [...]
Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna
03/11/2025
Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data ADELAIDE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , the largest premium full- [...]
VIVOLTA expands regenerative implant manufacturing capability with dedicated facility
03/11/2025
VIVOLTA expands regenerative implant manufacturing capability with dedicated facility New High Tech Campus Eindhoven site to enable electrospun medical implant production at scale Growth Momentum: Reflecting VIVOLTA’s [...]
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
03/11/2025
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy [...]
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
03/11/2025
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, [...]
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
02/11/2025
REYKJAVIK, ICELAND ( November 2, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. [...]
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
02/11/2025
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today [...]
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
02/11/2025
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug [...]
Fangzhou’s “XingJie” LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations
02/11/2025
SHENZHEN, China, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, was presented with a Generative AI Service Filing [...]
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
01/11/2025
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, announced yesterday, [...]
Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service
31/10/2025
WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that Chelsea Clinton, the longest-serving member of its [...]
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/10/2025
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of [...]
Edesa Biotech Announces Upcoming Conference Schedule
31/10/2025
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today [...]
Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembre 2025
31/10/2025
NEW YORK, 31 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]

Pages